低危甲状腺癌患者甲状腺切除术后不进行放射性碘治疗:前瞻性随机ESTIMABL2试验5年随访
ESTIMABL2多中心随机3期试验纳入低危分化型甲状腺癌患者,比较术后不进行放射性碘(131I)随访策略与术后131I治疗。5年随访时,无事件患者比例分别为93.2%和94.8%,差异为-1.6%(90%CI -4.5至1.4),证实非劣效性。
要点
- 低危分化型甲状腺癌术后不进行131I的随访策略在5年时非劣效于术后131I治疗。
- 5年无事件比例:无放射性碘组93.2% vs 放射性碘组94.8%,差异-1.6%(90%CI -4.5至1.4)。
- 无事件比例差异的90%CI下限未超过预设的非劣效界值-5%。
核心结论
- 在低危分化型甲状腺癌患者中,与术后131I治疗相比,不进行放射性碘的随访策略在5年时非劣效性得到证实。
- 对这些患者不进行术后消融而进行随访不会丧失机会。
研究设计与样本
- ESTIMABL2是一项多中心随机3期试验,纳入低危分化型甲状腺癌(pT1am或pT1b,N0或Nx)患者。
- 患者接受全甲状腺切除术伴或不伴预防性颈部淋巴结清扫,术后颈部超声无可疑发现,随机分配至无放射性碘组或放射性碘组(给予重组人促甲状腺激素后1.1 GBq-30 mCi)。
- 随访包括左甲状腺素治疗期间每年测定甲状腺球蛋白和甲状腺球蛋白抗体,奇数年进行颈部超声。
- 共入组776例患者(女性642例[82.7%],男性134例[17.3%],中位年龄52.9岁[IQR 42.6-63.1]),5年时可评估698例。
主要发现
- 5年时无事件患者比例:无放射性碘组93.2% vs 放射性碘组94.8%,差异-1.6%(90%CI -4.5至1.4)。
- 事件包括结构性或功能性异常(n=11)和生物学异常(n=31)。
关键数值与推荐
- 非劣效性界值:两组无事件比例及其CI差异不超过-5%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: ESTIMABL2, a multicentre randomised phase 3 trial in patients with low-risk differentiated thyroid cancer (ie, pT1am or pT1b, N0 [no evidence of regional nodal involvement] or Nx [involvement of regional lymph nodes that cannot be assessed in the absence of neck dissection]), showed the non-inferiority of a follow-up strategy without radioactive iodine (131I) administration compared with a postoperative 131I administration at 3 years post-randomisation. Here, we report a pre-specified analysis after 5 years of follow-up. METHODS: Patients treated with total thyroidectomy with or without prophylactic neck lymph node dissection, without postoperative suspicious findings on neck ultrasonography, were randomly assigned to the no-radioiodine group or to the radioiodine group (1·1 GBq-30 mCi after recombinant human thyrotropin-stimulating hormone). Follow-up consisted of annual thyroglobulin and thyroglobulin antibody determinations during levothyroxine treatment and neck ultrasonography in odd-numbered years. An event was defined as abnormal foci of 131I uptake on the post-treatment whole-body-scan requiring subsequent treatment, abnormal neck ultrasonography, elevated thyroglobulin levels, increasing titres or appearance of thyroglobulin antibody (using the same laboratory assay), or a combination of these definitions. Non-inferiority of the proportion of patients without an event in one group compared with the other at 5 years after randomisation was shown if this proportion and its CI did not differ by more than -5%. This study was registered on ClinicalTrials.gov (NCT01837745) and is completed. FINDINGS: Of the 776 patients (n=642 [82·7%] female and n=134 [17·3%] male, median age 52·9 years [IQR 42·6-63·1]) enrolled, 698 were evaluable at 5 years. The proportions of patients without events were 93·2% in the no-radioiodine group and 94·8% in the radioiodine group, for a difference of -1·6% (90% CI -4·5 to 1·4). Events consisted of structural or functional abnormalities (n=11) and biological abnormalities (n=31). INTERPRETATION: The non-inferiority of a follow-up strategy compared with postoperative 131I administration in low risk differentiated thyroid cancer was confirmed at 5 years. There is no loss of opportunity in following these patients without postoperative ablation. FUNDING: Programme de Recherche Hospitalier Clinique.
引用
- Leboulleux S, Bournaud C, Chougnet CN, et al. Thyroidectomy without radioiodine in patients with low-risk thyroid cancer: 5 years of follow-up of the prospective randomised ESTIMABL2 trial. Lancet Diabetes Endocrinol. 2024. PMID: 39586309. doi:10.1016/S2213-8587(24)00276-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。